Spriano F1, Chung EY1, Panini N2, Cascione L1,3, Rinaldi A1, Erba E2, Stathis A4, D'Incalci M2, Bertoni F1, Gatta R2.
Author information
1 - Università della Svizzera italiana (USI), Istituto Oncologico di Ricerca (IOR), Bellinzona, Switzerland.
2 - IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.
3 - Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland.
4 - Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland.
... In conclusion, trabectedin showed in vitro anti‐tumour activity in DLBCL and its mechanism of action included transcriptional inhibition of genes important for DLBCL proliferation and survival, possibly by reducing the binding of FLI1 to DNA. These data suggest that the use of trabectedin and its novel derivatives as anti‐lymphoma agents is worthy of further investigation.